These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

424 related items for PubMed ID: 25482512

  • 1. Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease.
    Matera MG, Capuano A, Cazzola M.
    Expert Rev Respir Med; 2015 Feb; 9(1):5-12. PubMed ID: 25482512
    [Abstract] [Full Text] [Related]

  • 2. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
    Dransfield MT, Feldman G, Korenblat P, LaForce CF, Locantore N, Pistolesi M, Watkins ML, Crim C, Martinez FJ.
    Respir Med; 2014 Aug; 108(8):1171-9. PubMed ID: 24998880
    [Abstract] [Full Text] [Related]

  • 4. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.
    Stynes G, Svedsater H, Wex J, Lettis S, Leather D, Castelnuovo E, Detry M, Berry S.
    Respir Res; 2015 Feb 15; 16(1):25. PubMed ID: 25849223
    [Abstract] [Full Text] [Related]

  • 5. Fluticasone furoate/vilanterol: a review of its use in chronic obstructive pulmonary disease.
    McKeage K.
    Drugs; 2014 Sep 15; 74(13):1509-22. PubMed ID: 25074268
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β2-agonists (ICS/LABA) in patients with uncontrolled asthma: An open-label, randomized, controlled trial.
    Devillier P, Humbert M, Boye A, Zachgo W, Jacques L, Nunn C, West S, Nicholls A, Antoun Z, Spinu L, Grouin JM.
    Respir Med; 2018 Aug 15; 141():111-120. PubMed ID: 30053956
    [Abstract] [Full Text] [Related]

  • 7. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial.
    Martinez FJ, Boscia J, Feldman G, Scott-Wilson C, Kilbride S, Fabbri L, Crim C, Calverley PM.
    Respir Med; 2013 Apr 15; 107(4):550-9. PubMed ID: 23332861
    [Abstract] [Full Text] [Related]

  • 8. The pharmacodynamics, pharmacokinetics, safety and tolerability of inhaled fluticasone furoate and vilanterol administered alone or simultaneously as fluticasone furoate/vilanterol.
    Kempsford R, Allen A, Bareille P, Hamilton M, Cheesbrough A.
    Clin Pharmacol Drug Dev; 2015 Jan 15; 4(1):2-11. PubMed ID: 27127998
    [Abstract] [Full Text] [Related]

  • 9. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
    Siler TM, Nagai A, Scott-Wilson CA, Midwinter DA, Crim C.
    Respir Med; 2017 Feb 15; 123():8-17. PubMed ID: 28137501
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT.
    Marín JM, Mateos L, Roldán J, Echave-Sustaeta JM, Pascual-Guardia S, Pardo MV, Velasco B, Jones CE, Kilbride S, Lipson DA.
    Ther Adv Respir Dis; 2020 Feb 15; 14():1753466620963021. PubMed ID: 33121372
    [No Abstract] [Full Text] [Related]

  • 11. Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPD.
    Caramori G, Chung KF, Adcock IM.
    Int J Chron Obstruct Pulmon Dis; 2014 Feb 15; 9():249-56. PubMed ID: 24596460
    [Abstract] [Full Text] [Related]

  • 12. Benefit and safety of fluticasone furoate/vilanterol in the Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD) according to baseline patient characteristics and treatment subgroups.
    Bakerly ND, Woodcock A, Collier S, Leather DA, New JP, Crawford J, Harvey C, Vestbo J, Boucot I.
    Respir Med; 2019 Feb 15; 147():58-65. PubMed ID: 30704700
    [Abstract] [Full Text] [Related]

  • 13. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial.
    Lin J, Kang J, Lee SH, Wang C, Zhou X, Crawford J, Jacques L, Stone S.
    Respir Med; 2015 Jan 15; 109(1):44-53. PubMed ID: 25524507
    [Abstract] [Full Text] [Related]

  • 14. Combination of fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease.
    Bollmeier SG, Prosser TR.
    Ann Pharmacother; 2014 Feb 15; 48(2):250-7. PubMed ID: 24259654
    [Abstract] [Full Text] [Related]

  • 15. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
    Hamilton M, Leggett R, Pang C, Charles S, Gillett B, Prime D.
    J Aerosol Med Pulm Drug Deliv; 2015 Dec 15; 28(6):498-506. PubMed ID: 26372465
    [Abstract] [Full Text] [Related]

  • 16. A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD.
    Bhatt SP, Dransfield MT, Cockcroft JR, Wang-Jairaj J, Midwinter DA, Rubin DB, Scott-Wilson CA, Crim C.
    Int J Chron Obstruct Pulmon Dis; 2017 Dec 15; 12():351-365. PubMed ID: 28176907
    [Abstract] [Full Text] [Related]

  • 17. Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma.
    Oliver A, VanBuren S, Allen A, Hamilton M, Tombs L, Inamdar A, Kempsford R.
    Clin Ther; 2014 Jun 01; 36(6):928-939.e1. PubMed ID: 24793536
    [Abstract] [Full Text] [Related]

  • 18. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.
    Kerwin EM, Scott-Wilson C, Sanford L, Rennard S, Agusti A, Barnes N, Crim C.
    Respir Med; 2013 Apr 01; 107(4):560-9. PubMed ID: 23352226
    [Abstract] [Full Text] [Related]

  • 19. Long-acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium.
    Pepin JL, Cockcroft JR, Midwinter D, Sharma S, Rubin DB, Andreas S.
    Chest; 2014 Dec 01; 146(6):1521-1530. PubMed ID: 25058845
    [Abstract] [Full Text] [Related]

  • 20. Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects.
    Malerba M, Nardin M, Santini G, Mores N, Radaeli A, Montuschi P.
    Ther Adv Respir Dis; 2018 Dec 01; 12():1753466618760779. PubMed ID: 29537340
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.